WOIPPY, France–(BUSINESS WIRE)–Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (the “Company”), a company specializing in molecular diagnostic solutions, healthcare software and services supporting clinical research, announces that it has made its Half-Year Financial Report for the period ended 30 June 2026 available to the public and filed it with the French Financial Markets Authority (Autorité des Marchés Financiers – AMF). The report is available on th